LYELL IMMUNOPHARMA INC (LYEL) Stock Analyst Ratings
NASDAQ:LYEL • US55083R2031
25.84 USD
+0.46 (+1.81%)
At close: Feb 13, 2026
25.25 USD
-0.59 (-2.28%)
After Hours: 2/13/2026, 8:22:25 PM
ChartMill assigns a Buy % Consensus number of 78% to LYEL. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 39.27. This target is 51.97% above the current price.
- LYEL was analyzed by 9 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about LYEL.
- In the last month the buy percentage rose by 30 points. So the trust of analysts is improving.
- LYEL was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-09 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-11-24 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-09-26 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2025-06-24 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-04-16 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-03-13 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-30 | B of A Securities | Downgrade | Buy -> Underperform |
| 2024-10-28 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-06-27 | B of A Securities | Maintains | Buy -> Buy |
| 2024-06-27 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-05-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-28 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-02 | HC Wainwright & Co. | Maintains | Buy |
| 2023-01-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-11-14 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-11-11 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-17 | HC Wainwright & Co. | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-01-06 | Morgan Stanley | Maintains | Overweight |
| 2021-07-12 | JP Morgan | Initiate | Overweight |
| 2021-07-12 | Goldman Sachs | Initiate | Buy |
| 2021-07-12 | B of A Securities | Initiate | Buy |
| 2021-07-12 | Morgan Stanley | Initiate | Overweight |
LYELL IMMUNOPHARMA INC / LYEL FAQ
What is the average price target for LYELL IMMUNOPHARMA INC (LYEL) stock?
9 analysts have analysed LYEL and the average price target is 39.27 USD. This implies a price increase of 51.97% is expected in the next year compared to the current price of 25.84.
What is the consensus rating for LYEL stock?
The consensus rating for LYELL IMMUNOPHARMA INC (LYEL) is 77.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.